|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
First, we conducted a histological analysis of FGF19-overexpressing Hep3B2.1-7 xenograft tumors collected from mice treated with lenvatinib.
|
30944079 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The inhibitory effect on tumor growth was investigated in 10 different liver cancer models <i>in vivo</i> The antibody specifically slowed tumor growth of models overexpressing FGF19 by up to 90% whereas tumor growth of models not expressing FGF19 was unaffected.
|
31350344 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These observations indicate that the FGF19/FGFR4 pathway may be involved in the development of neoplasia, and that FGF19 may be a valuable diagnostic marker for the identification of patients with colorectal adenomas.
|
30517925 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
SIGNIFICANCE: Fisogatinib elicited clinical responses in patients with tumor FGF19 overexpression in advanced HCC.
|
31575541 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Fisogatinib (BLU-554) is a potent and selective inhibitor of FGFR4 and demonstrates clinical benefit and tumor regression in patients with HCC with aberrant FGF19 expression.
|
31575540 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
These results suggest that ASP5878 is a potentially effective therapeutic agent for hepatocellular carcinoma patients with tumors expressing fibroblast growth factor 19.
|
27837028 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Fluorescence in situ hybridization analysis and quantitative real-time-PCR was used to detect FGF19 genetic amplification and FGF19 messenger RNA expression in LSCC tumor and paired adjacent samples.
|
28906590 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Ectopic FGF19 expression promotes EMT and invasion in epithelial-like HCC cells through repression of E-cadherin expression, whereas FGF19 knockdown enhances E-cadherin expression and hence diminishes EMT traits in mesenchymal-like HCC cells, suggesting FGF19 exerts its tumor progressing functions as an EMT inducer.
|
26498355 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, M70 inhibits FGF19-dependent tumor growth in a rodent model.
|
24728076 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
FGF19 silencing in prostate cancer cells expressing autocrine FGF19 decreased invasion and proliferation in vitro and tumor growth in vivo.
|
23440425 |
2013 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Univariate and multivariate analyses revealed that the tumor FGF19 mRNA expression was an independent prognostic factor for overall and disease-free survival.
|
22309595 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We showed that FGFR4 expression is markedly increased in high-grade PanIN and PDAC compared with that in normal and low-grade PanIN, and that FGFR4 stimulation by FGF19 of PDAC cells contributes to tumor suppression by increasing cell adhesion to extracellular matrix.
|
21109934 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Subsequent in vitro perturbation of FGFR4 signaling through both FGF19-stimulation and FGFR4 silencing confirmed a mechanistic link between FGFR4 activities and tumor aggressiveness.
|
19008009 |
2009 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our previous study has shown that FGF19 transgenic tumors have an activated Wnt-pathway phenotype.
|
18593907 |
2008 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
To test the importance of FGF19 for tumor growth, we developed an anti-FGF19 monoclonal antibody that selectively blocks the interaction of FGF19 with FGFR4.
|
17599042 |
2008 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Consistent with chronic activation of the Wingless/Wnt pathway, 44% of the hepatocellular tumors from FGF19 transgenic mice had nuclear staining for beta-catenin.
|
12057932 |
2002 |